Highlights Olema Pharmaceuticals, Inc.

Equities

OLMA

US68062P1066

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
13.13 ^USD	-1.20%		+35.64%	-6.41%

May. 15	Olema Pharmaceuticals, Inc. Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 Esmo Breast Cancer Congress	CI
May. 08	Olema Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Olema Pharmaceuticals, Inc. Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 Esmo Breast Cancer Congress	May. 15	CI
Olema Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Olema Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 11	CI
Olema Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 11	CI
Olema Oncology Announces Publication of Data Highlighting Palazestrant?s Ability to Inhibit Wild-Type and Mutant Er+ Breast Cancer Both as Monotherapy and in Combination with Cdk4/6 Inhibitors	Mar. 06	CI
Olema Pharmaceuticals, Inc. Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate	Jan. 08	CI
Olema Pharmaceuticals, Inc. Announces Palazestrant Demonstrates Attractive Combinability with Cdk4/6 Inhibitors Ribociclib and Palbociclib in Phase 1B/2 Studies	Dec. 05	CI
Olema Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Olema Pharmaceuticals, Inc. Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant	23-10-23	CI
Olema Pharmaceuticals, Inc. Announces Phase 2 Monotherapy Clinical Results to Be Presented At the 2023 Esmo Congress	23-10-16	CI
Olema Pharmaceuticals Broadens Clinical Collaboration With Novartis to Increase Size of Breast Cancer Study	23-10-10	MT
Olema Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Olema Oncology Announces OP-1250 Continues to Demonstrate Attractive Combinability with CDK4/6 Inhibitor Palbociclib in Phase 1B/2 Study	23-05-11	CI
Olema Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
OLEMA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-03-09	AQ
Olema Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-09	CI
Olema Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-09	CI
Olema Pharmaceuticals, Inc. Announces OP-1250 Demonstrates Attractive Combinability with CDK 4/6 Inhibitor Palbociclib in Phase 1b Dose Escalation Study	22-12-07	CI
OLEMA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-11-08	AQ
Olema Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-08	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Olema Pharmaceuticals, Inc.

Equities

OLMA

US68062P1066

Highlights

Filters